Cargando…

Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?

BACKGROUND: Pain in general and headache in particular are characterized by a change in activity in brain areas involved in pain processing. The therapeutic challenge is to identify drugs with molecular targets that restore the healthy state, resulting in meaningful pain relief or even freedom from...

Descripción completa

Detalles Bibliográficos
Autores principales: Straube, Andreas, Aicher, Bernhard, Fiebich, Bernd L, Haag, Gunther
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080296/
https://www.ncbi.nlm.nih.gov/pubmed/21453539
http://dx.doi.org/10.1186/1471-2377-11-43
_version_ 1782202091705466880
author Straube, Andreas
Aicher, Bernhard
Fiebich, Bernd L
Haag, Gunther
author_facet Straube, Andreas
Aicher, Bernhard
Fiebich, Bernd L
Haag, Gunther
author_sort Straube, Andreas
collection PubMed
description BACKGROUND: Pain in general and headache in particular are characterized by a change in activity in brain areas involved in pain processing. The therapeutic challenge is to identify drugs with molecular targets that restore the healthy state, resulting in meaningful pain relief or even freedom from pain. Different aspects of pain perception, i.e. sensory and affective components, also explain why there is not just one single target structure for therapeutic approaches to pain. A network of brain areas ("pain matrix") are involved in pain perception and pain control. This diversification of the pain system explains why a wide range of molecularly different substances can be used in the treatment of different pain states and why in recent years more and more studies have described a superior efficacy of a precise multi-target combination therapy compared to therapy with monotherapeutics. DISCUSSION: In this article, we discuss the available literature on the effects of several fixed-dose combinations in the treatment of headaches and discuss the evidence in support of the role of combination therapy in the pharmacotherapy of pain, particularly of headaches. The scientific rationale behind multi-target combinations is the therapeutic benefit that could not be achieved by the individual constituents and that the single substances of the combinations act together additively or even multiplicatively and cooperate to achieve a completeness of the desired therapeutic effect. As an example the fixesd-dose combination of acetylsalicylic acid (ASA), paracetamol (acetaminophen) and caffeine is reviewed in detail. The major advantage of using such a fixed combination is that the active ingredients act on different but distinct molecular targets and thus are able to act on more signalling cascades involved in pain than most single analgesics without adding more side effects to the therapy. SUMMARY: Multitarget therapeutics like combined analgesics broaden the array of therapeutic options, enable the completeness of the therapeutic effect, and allow doctors (and, in self-medication with OTC medications, the patients themselves) to customize treatment to the patient's specific needs. There is substantial clinical evidence that such a multi-component therapy is more effective than mono-component therapies.
format Text
id pubmed-3080296
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30802962011-04-21 Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics? Straube, Andreas Aicher, Bernhard Fiebich, Bernd L Haag, Gunther BMC Neurol Review BACKGROUND: Pain in general and headache in particular are characterized by a change in activity in brain areas involved in pain processing. The therapeutic challenge is to identify drugs with molecular targets that restore the healthy state, resulting in meaningful pain relief or even freedom from pain. Different aspects of pain perception, i.e. sensory and affective components, also explain why there is not just one single target structure for therapeutic approaches to pain. A network of brain areas ("pain matrix") are involved in pain perception and pain control. This diversification of the pain system explains why a wide range of molecularly different substances can be used in the treatment of different pain states and why in recent years more and more studies have described a superior efficacy of a precise multi-target combination therapy compared to therapy with monotherapeutics. DISCUSSION: In this article, we discuss the available literature on the effects of several fixed-dose combinations in the treatment of headaches and discuss the evidence in support of the role of combination therapy in the pharmacotherapy of pain, particularly of headaches. The scientific rationale behind multi-target combinations is the therapeutic benefit that could not be achieved by the individual constituents and that the single substances of the combinations act together additively or even multiplicatively and cooperate to achieve a completeness of the desired therapeutic effect. As an example the fixesd-dose combination of acetylsalicylic acid (ASA), paracetamol (acetaminophen) and caffeine is reviewed in detail. The major advantage of using such a fixed combination is that the active ingredients act on different but distinct molecular targets and thus are able to act on more signalling cascades involved in pain than most single analgesics without adding more side effects to the therapy. SUMMARY: Multitarget therapeutics like combined analgesics broaden the array of therapeutic options, enable the completeness of the therapeutic effect, and allow doctors (and, in self-medication with OTC medications, the patients themselves) to customize treatment to the patient's specific needs. There is substantial clinical evidence that such a multi-component therapy is more effective than mono-component therapies. BioMed Central 2011-03-31 /pmc/articles/PMC3080296/ /pubmed/21453539 http://dx.doi.org/10.1186/1471-2377-11-43 Text en Copyright ©2011 Straube et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Straube, Andreas
Aicher, Bernhard
Fiebich, Bernd L
Haag, Gunther
Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?
title Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?
title_full Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?
title_fullStr Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?
title_full_unstemmed Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?
title_short Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?
title_sort combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080296/
https://www.ncbi.nlm.nih.gov/pubmed/21453539
http://dx.doi.org/10.1186/1471-2377-11-43
work_keys_str_mv AT straubeandreas combinedanalgesicsinheadachepaintherapyshotgunapproachorprecisemultitargettherapeutics
AT aicherbernhard combinedanalgesicsinheadachepaintherapyshotgunapproachorprecisemultitargettherapeutics
AT fiebichberndl combinedanalgesicsinheadachepaintherapyshotgunapproachorprecisemultitargettherapeutics
AT haaggunther combinedanalgesicsinheadachepaintherapyshotgunapproachorprecisemultitargettherapeutics